PERSEUSNCT04458051TolebrutinibocrelizumabPPMSsecondary progressive MSprimary progressive MS
…ere, we present baseline characteristics of participants in the PERSEUS phase 3 trial ( NCT04458051), evaluating the efficacy, safety, …
1articles mentioning institutions
1institution mentions
1distinct institutions extracted
0%of mentions human-reviewed
Active filtersEntity: NCT04458051 ×
NCT04458051
This institution is selected. Its supporting articles are shown below.